TOMORROW’S TECHNOLOGY

TODAY’S CURES

WHAT WE DO

Fight Severe
Inflammation

Our Immune Modifying Particles (IMP) are derived from biodegradable polymer poly(lactic-co-glycolic-acid) (PLGA), and when modified and built using proprietary IMP technology, provide therapeutic relief in inflammatory conditions, including acute myocardial infarction and rare tropical diseases.

Target Autoimmune Diseases & Allergies

Our proprietary Tolerizing Immune Modifying Particle (TIMP) platform can be programmed to target autoimmune or allergic conditions by introducing disease-specific antigens to re-program the immune system.

Breakthrough Nanotechnology

Taken together, IMP and TIMP are break-through technologies that address a wide range of immunological therapeutic opportunities in a novel manner.

COMBINING MATERIAL SCIENCE AND IMMUNOLOGY TO CURE DISEASE

OUR TECHNOLOGY

The Cour particle platforms provide a novel and highly specific immune targeting capability which may be applied to severe inflammatory modulation, and immune (antigen) tolerization.

Unmatched Breakthrough

The TIMP and IMP platforms are a truly novel opportunity unmatched by current in-market and pipeline alternatives which primarily consist of toxic immune suppressants. These platforms have far-reaching implications across a wide-spectrum of valuable therapeutic indications.
Immune Modifying
Nanoparticles (IMP)
For severe inflammation
IMP_3

The particle design starts with an FDA approved co-polymer – PLGA

The particles target/bind inflammatory cells (monocytes) and eliminate them through normal metabolism

Reduction in circulating monocytes prevents tissue damage

Tolerizing Immune Modifying

Nanoparticles (TIMP)

For autoimmune conditions
TIMP_3

While the IMP particle surface provides the immune uptake, the interior core can be loaded with antigen

Tolerizing IMPs (TIMPs) are programmable for a number of autoimmune conditions

OUR PIPELINE AND PROGRAMS

Combining Immunology and Material Sciences to cure human disease

We have developed unique therapeutic platforms that will transform traditional approaches to how immune diseases are treated. Our team of physicians, researchers and leading pharmaceutical company collaborators understand the unique opportunities of nanotechnology-based therapy development, resulting in optimized development with the greatest chance of clinical success.
Cour_Pipeline_2

IMMUNE REPROGRAMMING

CELIAC DISEASE (TIMP–Gliadin)
ALLERGY (TIMP–Allergen)
RARE DISEASES (TIMP–Antigen)
ANTI-DRUG ANTIBODIES (TIMP–Protein Factor)

SEVERE INFLAMATION PROGRAMS

ACUTE MYOCARDIAL INFARCTION (IMP)
SEVERE MALARIA (IMP)

WHO WE ARE

We are a group of dedicated scientific, medical, and business professionals who are driven to find treatments and cures to a variety of diseases. By attacking the disease directly with our novel TIMP/IMP technology and working strategically with our medical and scientific partners we seek to provide treatments and cures previously unavailable to doctors and their patients.

OUR ECOSYSTEM